[Correspondence] Reassessing the 1  + 1 pneumococcal conjugate vaccine schedule

The primary endpoint selected by David Goldblatt and colleagues,1 which was used to support a pneumococcal conjugate vaccine (PCV) programme consisting of one primary dose and one booster dose (1  + 1), is a poor indicator of protection during the first year of life, and contrary to O'Brien's Comment,2 this programme is not likely to be feasible for implementation in countries supported by Gavi, the Vaccine Alliance.

Source: The Lancet Infectious Diseases - March 22, 2018 Category: Infectious Diseases Authors: Stephanie Perniciaro, Mark van der Linden Tags: Correspondence Source Type: research